Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
CYTK

CYTK - Cytokinetics Inc Stock Price, Fair Value and News

59.60USD-0.32 (-0.53%)Delayed

Market Summary

CYTK
USD59.60-0.32
Delayed
-0.53%

CYTK Alerts

  • 2 major insider sales recently.

CYTK Stock Price

View Fullscreen

CYTK RSI Chart

CYTK Valuation

Market Cap

6.2B

Price/Earnings (Trailing)

-11.78

Price/Sales (Trailing)

1.7K

EV/EBITDA

287.64

Price/Free Cashflow

-14.79

CYTK Price/Sales (Trailing)

CYTK Profitability

EBT Margin

-471.88%

Return on Equity

133.93%

Return on Assets

-65.66%

Free Cashflow Yield

-6.76%

CYTK Fundamentals

CYTK Revenue

Revenue (TTM)

3.8M

Rev. Growth (Yr)

-81.9%

Rev. Growth (Qtr)

-50.06%

CYTK Earnings

Earnings (TTM)

-530.6M

Earnings Growth (Yr)

-3.28%

Earnings Growth (Qtr)

0.96%

Breaking Down CYTK Revenue

Last 7 days

-4.0%

Last 30 days

-12.3%

Last 90 days

-22.5%

Trailing 12 Months

58.6%

How does CYTK drawdown profile look like?

CYTK Financial Health

Current Ratio

7.19

Debt/Equity

-0.14

Debt/Cashflow

-7.42

CYTK Investor Care

Shares Dilution (1Y)

9.63%

Diluted EPS (TTM)

-5.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20243.8M000
202398.1M10.0M7.8M7.5M
202276.5M82.5M88.5M94.6M
202158.6M57.8M21.6M70.4M
202022.2M18.7M54.3M55.8M
201934.7M35.6M31.0M26.9M
201817.9M22.4M27.0M31.5M
2017102.1M99.4M46.5M13.4M
201632.7M31.9M83.0M106.4M
201543.4M42.1M40.7M28.7M
201437.8M44.6M49.5M46.9M
20136.6M5.7M8.5M30.6M
20125.1M5.8M6.1M7.6M
20112.9M3.3M4.3M4.0M
2010055.2M28.9M2.6M
200900081.5M

Tracking the Latest Insider Buys and Sells of Cytokinetics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 07, 2024
malik fady ibraham
sold
-1,012,270
65.11
-15,547
evp research & development
May 07, 2024
malik fady ibraham
acquired
94,620
6.67
14,186
evp research & development
Apr 25, 2024
henderson john t
sold
-681,672
64.54
-10,562
-
Apr 12, 2024
malik fady ibraham
gifted
-
-
-150
evp research & development
Apr 09, 2024
malik fady ibraham
acquired
190,795
6.67
28,605
evp research & development
Apr 09, 2024
malik fady ibraham
sold
-2,422,920
74.3112
-32,605
evp research & development
Mar 14, 2024
callos andrew
acquired
-
-
16,941
evp, chief commercial officer
Mar 14, 2024
blum robert i
acquired
-
-
61,490
president & ceo
Mar 14, 2024
wong robert
acquired
-
-
4,079
vp, chief accounting officer
Mar 14, 2024
malik fady ibraham
acquired
-
-
42,666
evp research & development

1–10 of 50

Which funds bought or sold CYTK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
COMERICA BANK
added
185
5,343,710
9,170,820
0.04%
May 16, 2024
Murchinson Ltd.
added
56.68
1,830,160
7,627,620
0.64%
May 16, 2024
JANE STREET GROUP, LLC
added
247
14,167,900
21,563,500
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-49.07
-10,853,700
8,575,700
-%
May 16, 2024
Virtus Investment Advisers, Inc.
sold off
-100
-393,906
-
-%
May 16, 2024
CASTLEARK MANAGEMENT LLC
new
-
1,470,910
1,470,910
0.06%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-3.59
-1,467,470
6,240,490
0.01%
May 15, 2024
FARALLON CAPITAL MANAGEMENT LLC
reduced
-90.59
-83,638,800
7,179,260
0.03%
May 15, 2024
BRIDGER MANAGEMENT, LLC
added
207
2,965,940
4,845,300
2.18%
May 15, 2024
ORBIMED ADVISORS LLC
new
-
47,864,100
47,864,100
0.88%

1–10 of 32

Are Funds Buying or Selling CYTK?

Are funds buying CYTK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CYTK
No. of Funds

Unveiling Cytokinetics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
11.24%
11,016,889
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 08, 2024
wellington management group llp
6.66%
6,530,884
SC 13G/A
Jan 25, 2024
state street corp
6.01%
5,893,358
SC 13G/A
Jan 22, 2024
blackrock inc.
16.4%
16,102,070
SC 13G/A
Feb 10, 2023
blackrock inc.
16.7%
15,767,874
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
10.64%
10,073,094
SC 13G/A
Feb 06, 2023
wellington management group llp
6.91%
6,542,724
SC 13G
Feb 03, 2023
state street corp
5.33%
5,044,914
SC 13G/A

Recent SEC filings of Cytokinetics Inc

View All Filings
Date Filed Form Type Document
May 17, 2024
8-K
Current Report
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 16, 2024
4
Insider Trading
May 13, 2024
8-K
Current Report

Peers (Alternatives to Cytokinetics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
28.49% 6.05%
-8.53
7.44
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
18.9B
2.0B
2.79% -21.33%
-56.9
9.43
75.20% 68.82%
14.7B
2.5B
-14.30% -15.94%
71.65
5.96
13.74% 186.89%
12.8B
3.8B
8.33% -10.25%
17.2
3.4
8.58% 129.81%
MID-CAP
5.6B
107.9M
20.58% 115.45%
-10.31
48.09
54.84% -28.31%
5.0B
524.1M
-13.99% -52.79%
-12.02
9.57
394.93% 39.61%
3.6B
251.0M
9.96% -0.29%
-12.28
14.5
73.58% -86.73%
3.1B
240.7M
9.94% -31.73%
-6.53
12.77
-1.03% -213.43%
2.4B
813.8M
-14.08% -36.34%
-1.4K
3
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
3.06% 35.16%
29.91
4.73
60.38% -34.49%
1.8B
996.6M
233.93% 75.07%
-4.58
1.83
-26.66% 65.49%
480.9M
881.7K
21.10% 351.81%
-14.25
481.06
-77.61% 33.36%
310.9M
4.9M
8.40% 53.85%
-2.49
63.89
-54.97% 48.23%
17.1M
2.1M
4.76% 108.64%
-0.74
7.61
-13.45% 69.54%

Cytokinetics Inc News

Latest updates
MarketBeat46 hours ago
Nasdaq13 May 202408:21 pm
Genetic Engineering & Biotechnology News4 months ago

Cytokinetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-50.1%1.002.000.001.005.002.003.0089.0072.0056.005.003.007.007.0042.004.004.005.006.007.008.00
Operating Expenses-1.6%12712912312312912911110079.0077.0075.0058.0047.0043.0037.0036.0034.0029.0030.0034.0033.00
  S&GA Expenses-100.0%-44.0040.0040.0050.0054.0048.0043.0033.0034.0026.0021.0016.0014.0012.0014.0012.0011.0010.0010.009.00
  R&D Expenses-4.0%82.0085.0083.0083.0079.0075.0063.0057.0046.0043.0048.0036.0032.0029.0024.0022.0022.0018.0020.0024.0024.00
EBITDA Margin106.3%6.16*2.99*2.27*1.70*0.12*0.08*0.04*0.00*0.01*0.01*0.03*0.01*---------
Interest Expenses-0.9%7.007.007.007.007.007.007.003.003.004.004.004.004.004.004.004.004.003.001.001.001.00
EBT Margin-100.7%-4.72*-2.35*-2.27*-1.78*-0.18*-0.19*-0.20*-0.21*-0.23*-0.25*-0.82*-0.31*---------
Net Income1.0%-135-136-129-128-131-137-142-19.82-89.44-30.57-76.09-61.55-47.10-43.93-3.17-40.78-39.40-30.64-29.57-32.11-29.37
Net Income Margin-102.3%-141.41*-69.89*-67.40*-54.22*-4.39*-4.11*-3.19*-2.62*-3.37*-3.06*-10.61*-2.69*---------
Free Cashflow-74.7%-129-74.11-96.43-122-122-101-90.37-91.33-27.75-62.49-54.47-38.29---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-2.0%8088247417808901,0151,076772856841828564577534474232257290187198199
  Current Assets1.7%639628561587681795884602624536495364433474418219226234177185186
    Cash Equivalents6.2%12011310069.0010266.0010694.0011511391.0037.0045.0083.0020161.0050.0036.0040.0034.0039.00
  Net PPE-1.1%68.0069.0076.0077.0079.0080.0080.0079.0076.0073.0054.0037.0023.0013.008.006.005.005.004.003.003.00
Liabilities-0.5%1,2041,2111,1791,1131,1191,1231,092660740597579548509420325311302301207203195
  Current Liabilities-13.5%89.0010378.0066.0075.0085.0076.0067.0067.0072.0081.0062.0036.0031.0028.0023.0021.0026.0022.0022.0026.00
  Long Term Debt-2.7%57.0058.0061.0062.0064.0064.0064.0062.0061.0047.0030.0036.0041.0046.0046.0046.0045.0045.0045.0044.0036.00
    LT Debt, Current14.3%12.0010.00---1.00----17.0011.006.00-------6.00
    LT Debt, Non Current-100.0%-58.0061.0062.0064.0064.0064.0062.0061.0047.0030.0036.0041.0046.0046.0046.0045.0045.0045.0044.0036.00
Shareholder's Equity-2.5%-396-386---229-107-11111624424916.0068.00113150-----3.00
  Retained Earnings-7.0%-2,247-2,100-1,975-1,845-1,700-1,585-1,448-1,306-1,286-1,207-1,177-1,101-1,039-992-948-945-904-865-834-804-772
  Additional Paid-In Capital7.3%1,8521,7261,5371,5141,4901,4821,4381,4221,4061,4521,4261,1171,1071,1051,097866857853814799775
Shares Outstanding-100.0%-102---95.00---85.00---71.00---59.00---
Float----2,000---2,000---1,443---1,413---653-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-74.9%-129-74.03-96.21-121-122-98.19-84.04-90.47-26.81-44.74-38.77-29.50-29.5252.0014.00-27.44-30.13-19.05-20.27-24.68-26.91
  Share Based Compensation10.9%22.0019.0019.0019.0015.0013.0013.0012.009.007.008.007.005.005.005.005.004.003.003.003.002.00
Cashflow From Investing140.1%33.00-81.4173.0082.0016529.00-29265.00-64.2847.00-20819.00-5.28-173-10135.0043.00-10514.00-2.7720.00
Cashflow From Financing-38.5%10416954.005.00-7.1830.003893.0094.0020.003013.00-3.604.002264.00-0.0112112.0022.004.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CYTK Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 835$ 4,613
Operating expenses:  
Research and development81,57079,421
General and administrative45,50049,665
Total operating expenses127,070129,086
Operating loss(126,235)(124,473)
Interest expense(7,103)(6,961)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements(10,218)(6,280)
Interest and other income, net7,9136,425
Net loss$ (135,643)$ (131,289)
Net loss per share - basic$ (1.33)$ (1.38)
Net loss per share - diluted$ (1.33)$ (1.38)
Weighted-average number of shares used in computing net loss per share - basic101,92495,164
Weighted-average number of shares used in computing net loss per share - diluted101,92495,164
Other comprehensive (loss) gain:  
Unrealized (loss)/gain on available-for-sale securities, net$ (556)$ 1,945
Foreign currency translation adjustments270
Comprehensive loss(136,172)(129,344)
Research and Development Revenues [Member]  
Revenues:  
Total revenues8352,113
Milestone Revenues [Member]  
Revenues:  
Total revenues$ 0$ 2,500

CYTK Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 119,976$ 113,024
Short-term investments498,985501,800
Accounts receivable8341,283
Prepaid expenses and other current assets18,90911,944
Total current assets638,704628,051
Long-term investments15,37640,534
Property and equipment, net68,01868,748
Operating lease right-of-use assets78,17078,987
Other assets7,8147,996
Total assets808,082824,316
Current liabilities:  
Accounts payable12,96721,507
Accrued liabilities40,12342,641
Short-term operating lease liabilities18,23017,891
Current portion of long-term debt11,52010,080
Other current liabilities6,01510,559
Total current liabilities88,855102,678
Term loan, net56,82258,384
Convertible notes, net549,790548,989
Liabilities related to revenue participation right purchase agreements, net390,219379,975
Long-term operating lease liabilities118,554120,427
Other non-current liabilities2186
Total liabilities1,204,2421,210,639
Commitments and contingencies
Stockholders' deficit:  
Preferred stock00
Common stock105102
Additional paid-in capital1,852,1551,725,823
Accumulated other comprehensive loss(539)(10)
Accumulated deficit(2,247,881)(2,112,238)
Total stockholders' deficit(396,160)(386,323)
Total liabilities and stockholders' deficit$ 808,082$ 824,316
CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEcytokinetics.com
 INDUSTRYBiotechnology
 EMPLOYEES409

Cytokinetics Inc Frequently Asked Questions


What is the ticker symbol for Cytokinetics Inc? What does CYTK stand for in stocks?

CYTK is the stock ticker symbol of Cytokinetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cytokinetics Inc (CYTK)?

As of Fri May 17 2024, market cap of Cytokinetics Inc is 6.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYTK stock?

You can check CYTK's fair value in chart for subscribers.

What is the fair value of CYTK stock?

You can check CYTK's fair value in chart for subscribers. The fair value of Cytokinetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cytokinetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CYTK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cytokinetics Inc a good stock to buy?

The fair value guage provides a quick view whether CYTK is over valued or under valued. Whether Cytokinetics Inc is cheap or expensive depends on the assumptions which impact Cytokinetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYTK.

What is Cytokinetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CYTK's PE ratio (Price to Earnings) is -11.78 and Price to Sales (PS) ratio is 1.67 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYTK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cytokinetics Inc's stock?

In the past 10 years, Cytokinetics Inc has provided 0.298 (multiply by 100 for percentage) rate of return.